Literature DB >> 18688210

D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats.

Nathalie Ginovart1, Alan A Wilson, Doug Hussey, Sylvain Houle, Shitij Kapur.   

Abstract

Long-term occupancy of dopamine D(2)-receptors, as achieved by chronic treatment with antipsychotics, leads to D(2)-receptor upregulation, and this upregulation is thought to be responsible for loss of efficacy and development of tardive dyskinesia. However, little is known about the parameters of D(2)-receptor blockade (duration and percentage of blockade) that lead to upregulation. In this study, we investigated the effects of different degrees (60 vs >80%) and durations (a transient peak vs 24 h/day) of D(2)-receptor blockade on inducing this upregulation. These different patterns of D(2)-receptor occupancy kinetics were produced in cats using bolus vs constant infusion of haloperidol for 4 weeks. D(2)-receptors were measured using positron emission tomography and Scatchard analyses of [(11)C]raclopride binding, before and after withdrawal of treatment. Continuously high (80% for 24 h/day) D(2)-receptor blockade led to a robust upregulation of striatal D(2)-receptors that was maximal at 1-week withdrawal (35+/-5%) and still detectable at 2-week withdrawal (20+/-3%). This pattern of D(2)-receptor blockade also induced behavioral tolerance to the effect of haloperidol on spontaneous locomotor activity. Continuously moderate (60% for 24 h/day) or transiently high (80% for a few hours/day) D(2)-receptor blockade did not produce any of these effects. The long-term effect of haloperidol on D(2)-receptor density and behavioral tolerance thus appears to be dependent not only on a critical threshold of D(2)-receptor blockade but also on the daily duration of D(2)-receptors blockade. This suggests that as far as antipsychotics are concerned, not only dose but disbursment throughout the day have an impact on eventual pharmacodynamic and behavioral outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688210     DOI: 10.1038/npp.2008.116

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  31 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Quantitative PET imaging of radioligands with slow kinetics in human brain.

Authors:  Sandra M Sanabria-Bohórquez; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-25       Impact factor: 9.236

3.  D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.

Authors:  Mark E Schmidt; Peter de Boer; Randolph Andrews; Martine Neyens; Stefaan Rossenu; Demiana William Falteos; Erik Mannaert
Journal:  Psychopharmacology (Berl)       Date:  2012-07-07       Impact factor: 4.530

Review 4.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

5.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

Review 6.  [Basic principles of therapy with neuropsychotropic drugs].

Authors:  G Gründer; T Veselinović; M Paulzen
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

Review 7.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

8.  Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.

Authors:  Devinder Arora; Jayesh Mudgal; Madhavan Nampoothiri; Sanchari Basu Mallik; Manas Kinra; Susan Hall; Shailendra Anoopkumar-Dukie; Gary D Grant; Chamallamudi Mallikarjuna Rao
Journal:  Metab Brain Dis       Date:  2018-03-07       Impact factor: 3.584

9.  Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.

Authors:  Haiyun Xu; Hong-Ju Yang; Bryan McConomy; Ronald Browning; Xin-Min Li
Journal:  Front Behav Neurosci       Date:  2010-03-18       Impact factor: 3.558

10.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.